他汀类药物对非终末期慢性肾病患者心血管保护作用的有效性及安全性文献分析被引量：15

Efficacy and Safety of Statins in the Cardiovascular Protection of Patients With Non-terminal Chronic Kidney Disease:Literature Analysis

下载PDF

导出

摘要慢性肾脏病患者心血管疾病的发生率和病死率明显上升,血脂异常是慢性肾脏病患者发生心血管疾病的危险因素之一。他汀类药物是心血管疾病防治的核心药物之一,但是对于慢性肾脏病的不同阶段,他汀类药物的有效性和安全性仍存在争议。本文系统复习了近年来国内外相关的研究,客观评估他汀类药物在非终末期慢性肾脏病患者中的疗效和安全性,帮助临床合理用药。 The morbidity and mortality of cardiovascular disease are high among patients with chronic kidney disease,and dyslipidemia is one of the risk factors. Statins are core drugs for the prevention and treatment of cardiovascular disease,while it is still controversial on the efficacy and safety of statins on patients with chronic kidney disease at different stages. The paper made a review of major relevant researches in China and abroad and objectively evaluate the efficacy and safety of statins for patients with non- terminal chronic kidney diseases with a view to provide references for clinical rational drug use.

作者李舍予侯清涛田浩明

机构地区四川大学华西医院内分泌代谢科

出处《中国全科医学》 CAS CSCD 北大核心 2016年第6期633-638,共6页 Chinese General Practice

基金国家自然科学基金资助项目(81400811) 四川省卫生厅科研课题(130029 150149)

关键词肾病他汀类药物透析治疗结果药物毒性综述文献(主题) Nephrosis Statins Dialysis Treatment outcome Drug toxicity Review literature as topic

分类号 R692 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献16

1Gansevoort RT, Correa - Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk : epidemiology, mechanisms, and prevention [J]. Lancet, 2013, 382 (9889): 339-352.
2Pinkau T, Hilgers KF, Veelken R, et al. How does minor renal dysfunction influence cardiovascular risk and the management of cardiovascular disease? [J]. J Am Soc Nephrol, 2004, 15 (3): 517 -523.
3National Kidney Foundation. KDIGO clinical practice guideline for lipid management in chronic kidney disease [ J ]. Kidney Int Suppl, 2013, 3 (3): 259-305.
4Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States [ Jl. JAMA, 2007, 298 (17) : 2038 - 2047.
5Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross- sectional survey [ J]. Lancet, 2012, 379 (9818): 815-822.
6Mihos CG, Santana O. Pleiotropie effects of the HMG-CoA reductase inhibitors [J]- IntJGenMed, 2011, 4:261-271.
7Mason JC. The statins - therapeutic diversity in renal disease? [ J ]. Curr Opin Nephrol Hypertens, 2005, 14 (1) : 17 -24.
8Pasternak RC, Smith SC Jr, Bairey - Merz CN, et al. ACC/AHA/ NHLB1 clinical advisory" on the use and safety of statins [ J ]. J Am Coil Cardiol, 2002, 40 (3): 567-572.
9Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions [ J]. Circulation, 2004, 109 (23 Suool I) : Ⅲ50 -57.
10Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta analysis of randomised statin trials [J]. Lancet, 2010, 375 (9716): 735-742.